This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (96)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Men's Health, Other  • Lipids and Lipid Disorders  • Alert me on articles by topic

Sharon A. Riddler, MD, MPH; Ellen Smit, PhD; Stephen R. Cole, PhD; Rui Li, MS; Joan S. Chmiel, PhD; Adrian Dobs, MD; Frank Palella, MD; Barbara Visscher, MD, DrPH; Rhobert Evans, PhD; Lawrence A. Kingsley, DrPH

JAMA. 2003;289:2978-2982.

Context  Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values.

Objective  To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation.

Design, Setting, and Participants  The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002.

Main Outcome Measures  Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit.

Results  Among the 50 men, notable declines in mean serum TC (–30 mg/dL [-0.78 mmol/L]), HDL-C (–12 mg/dL [-0.31 mmol/L]), and LDL-C values (–22 mg/dL [-0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (-0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL).

Conclusions  Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.

Author Affiliations: University of Pittsburgh, Pittsburgh, Pa (Drs Riddler, Evans, and Kingsley); State University of New York at Buffalo (Dr Smit); Johns Hopkins University, Baltimore, Md (Drs Cole and Dobs, and Ms Li); Northwestern University, Chicago, Ill (Drs Chmiel and Palella); and University of California, Los Angeles (Dr Visscher).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aortic Stiffness in Untreated Adult Patients With Human Immunodeficiency Virus Infection
Schillaci et al.
Hypertension 2008;52:308-313.
ABSTRACT | FULL TEXT  

State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary
Grinspoon et al.
Circulation 2008;118:198-210.
FULL TEXT  

Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy
Currier et al.
Circulation 2008;118:e29-e35.
FULL TEXT  

Know Your Patient: What Conditions Affect Initial HIV Treatment Success?
Hodder
J Int Assoc Physicians AIDS Care (Chic Ill) 2008;7:S5-S9.
ABSTRACT  

Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
Negredo et al.
J Antimicrob Chemother 2008;61:400-404.
ABSTRACT | FULL TEXT  

Multiple Subcutaneous Lipomas Induced by HAART in the Absence of Protease Inhibitors
Balestreire et al.
Arch Dermatol 2007;143:1596-1597.
FULL TEXT  

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men
May et al.
Int J Epidemiol 2007;36:1309-1318.
ABSTRACT | FULL TEXT  

Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
Triant et al.
J. Clin. Endocrinol. Metab. 2007;92:2506-2512.
ABSTRACT | FULL TEXT  

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
The DAD Study Group
NEJM 2007;356:1723-1735.
ABSTRACT | FULL TEXT  

Effects of High-Intensity Endurance and Resistance Exercise on HIV Metabolic Abnormalities: A Pilot Study
Robinson et al.
Biol Res Nurs 2007;8:177-185.
ABSTRACT  

Carotid Intimal Medial Thickness in Human Immunodeficiency Virus-Infected Women: Effects of Protease Inhibitor Use, Cardiac Risk Factors, and the Metabolic Syndrome
Johnsen et al.
J. Clin. Endocrinol. Metab. 2006;91:4916-4924.
ABSTRACT | FULL TEXT  

Endothelial function in HIV-infected patients with low or mild cardiovascular risk
Blanco et al.
J Antimicrob Chemother 2006;58:133-139.
ABSTRACT | FULL TEXT  

What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection
Hsue and Waters
Circulation 2005;112:3947-3957.
ABSTRACT | FULL TEXT  

Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Arch Intern Med 2005;165:2541-2541.
FULL TEXT  

Impact of Treatment With Protease Inhibitors on Aortic Stiffness in Adult Patients With Human Immunodeficiency Virus Infection
Schillaci et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:2381-2385.
ABSTRACT | FULL TEXT  

Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy
Thomas-Geevarghese et al.
Am. J. Clin. Nutr. 2005;82:146-154.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Brown et al.
Arch Intern Med 2005;165:1179-1184.
ABSTRACT | FULL TEXT  

Postprandial Lipoprotein Changes in Patients Taking Antiretroviral Therapy for HIV Infection
Stein et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:399-405.
ABSTRACT | FULL TEXT  

Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon and Carr
NEJM 2005;352:48-62.
FULL TEXT  

The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens
Arribas
J Antimicrob Chemother 2004;54:587-592.
ABSTRACT | FULL TEXT  

HIV Infection and Cardiovascular Disease -- Is There Really a Link?
Sklar and Masur
NEJM 2003;349:2065-2067.
FULL TEXT  

JournalScan
Malik
Heart 2003;89:1119-1120.
FULL TEXT  

A New Theory on Lipid Elevations During Antiretroviral Therapy
JWatch Infect. Diseases 2003;2003:2-2.
FULL TEXT  

Antiretrovirals and Cardiovascular Disease: Is HAART Bad for Your Heart?
AIDS Clin Care 2003;2003:1-1.
FULL TEXT  

Lipids: The Before-and-After Test
AIDS Clin Care 2003;2003:4-4.
FULL TEXT